Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Allovir, Ampio, Arca, AVM, Celltrion, Eisai, Epimab, Equillium, Harbour Biomed, Hutchison China Meditech, I-Mab, Junshi, Mateon, Morphosys, Sorrento, Takeda.